Abstract: The invention relates to a particulate product comprising at least 10 wt. % of the coated lactate particles having the following characteristics: comprising one or more carrier particles containing at least 80 wt. % of calcium lactate component selected from calcium lactate hydrates, calcium lactate anhydrous and combinations thereof; comprising a coating layer that covers the one or more carrier particles, said coating layer containing at least 60 wt. % of sodium lactate; containing sodium and calcium in a molar ratio of 2.1:1 to 5:1; and a particle size in the range of 120 to 1,200 ?m. The coated lactate particles in the particulate product are very stable, even though the sodium lactate in the coating layer is in direct contact with the surrounding atmosphere. The particulate product can suitably be used in the preparation of foodstuffs and beverages.

Abstract: An aqueous disinfecting solution having a pH of from about 0.5 to about 6 consists essentially of hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the total solution, at least one anionic surfactant in a concentration of from about 0.02 to about 8 w/w % of the total solution, and at least one additional ingredient chosen from benzyl alcohol, an alcohol comprising one to six carbon atoms, and mixtures thereof, in a concentration of from about 0.1 to about 10 w/w % of the total solution.

Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.

Abstract: A ‘bioactive’ composition that has one or more oligogalacturonans ((1?4)-?-D-galacturonan) or any other oligosaccharides (oligoguluronans) that may present an ‘egg box’ conformation, this conformation being further stabilized by one or more polycationic saccharide(s), preferably either a chitosan oligosaccharide or a chitosan polysaccharide. A method prepares this composition and it is used, in medical, pharmaceutical, agricultural, nutraceutical, food, feed, textile, cosmetic, industrial and/or environmental applications.

Abstract: A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth regulator (IGR). The topical insecticide preparation can be packaged together or packaged so that the first and second pyrethroid insecticides are stored separately prior to administration of the insecticide preparation to the animal. The combination of the first and second pyrethroid insecticides with an insect growth regulator results in an insecticide preparation formulated to have enhanced insecticidal activity against fleas and ticks compared to the effectiveness of the first and second insecticides used alone.

Abstract: The present invention relates to stable dosage forms and compositions of levodopa and carbidopa for the treatment of patients suffering from Parkinson's disease. The dosage forms and compositions comprise both solid and liquid formulations and result in stable pharmaceutical products. Such dosage forms and compositions comprise a metal chelator and a levodopa concentration from about 1 mg/mL to about 30 mg/mL.

Abstract: A skin disinfectant in ready-to-use concentrated liquid or dry powdered form. Ready-to-use liquid forms have a pH of from about 2 to about 6 and include: (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w of the solution; (b) at least one surfactant chosen from imidazoline derivatives, alkyl betaines, alkyl amidopropyl betaine amides, alkyl amidopropyl betaines, alkylsulfo betaines, amine oxides and derivatives thereof in a concentration of from about 0.01 to about 15% w/w of the solution; (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4% w/w of the solution; (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w of the solution; and (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w of the solution.

Abstract: The present invention provides a new stable pharmaceutical composition of erythropoietin (EPO) that is stabilized with PVP.

Abstract: Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

Abstract: An aqueous disinfecting solution having a pH from about 0.5 to about 6 and consisting essentially of hydrogen peroxide in a concentration from about 0.05 to about 8 w/w % of the total solution; at least one anionic surfactant in a concentration from about 0.02 to about 8 w/w % of the total solution, selected from sulfonated C12 to C22 carboxylic acids and alkali metal, ammonium, calcium and magnesium salts thereof; naphthalene sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; C8 to C22 alkyl sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; and alkyl or alkenyl esters or diesters of sulfosuccinic acids in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms and alkali metal, ammonium, calcium and magnesium salts thereof; and benzyl alcohol in a concentration from about 0.1 to about 10 w/w % of the solution.

Abstract: The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.

Abstract: A method of formulating insulin compositions comprises preparing a carrier having a phosphatidylcholine component which entraps insulin, stabilizing insulin compositions at room temperatures.

Abstract: A fat emulsion comprises a prostaglandin as an active ingredient, the fat emulsion comprising a phospholipid that comprises phosphatidylcholine (PC) and phosphatidylglycerol (PG) and has a ratio of PC to PG (PC:PG) of 85:15 to 99.7:0.3.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.

Abstract: A method of making a composition having the property of being able to store chlorine dioxide includes mixing an aqueous chlorine dioxide solution with a superabsorbent, water-soluble polymer that is substantially unreactive with chlorine dioxide and permitting a mixture formed thereby to form one of a gel and a solid composition. A method of delivering chlorine dioxide includes providing a gel or solid composition as described and degelling the gel or dissolving the solid composition to dispense the chlorine dioxide therefrom. A method of disinfecting a target such as water, wastewater, or a surface comprises delivering chlorine dioxide as above and permitting the polymer to precipitate out of the mixture. Aqueous chlorine dioxide is then recovered and applied to the target.

Abstract: A liquid kelp formulation includes an enzyme inactivating component and a preservative to extend the shelf life of the formulation in terms of growth hormones. The formulation can also include a fertilizing additive, and a surfactant. A system is also provided whereby the kelp is maintained in solid form, and dissolved in water just prior to use. The solid form kelp and/or water can include additives, or additives in separate form, if used, can be added to either the kelp or the kelp solution.

Abstract: A growth hormone formulation includes an enzyme inactivating component and a preservative. The formulation can also include a fertilizing additive, and a surfactant. The growth hormone can be a natural one such as that found in kelp or a synthetic one or a combination of both.

Abstract: A growth hormone formulation includes an enzyme inactivating component and a preservative. The formulation can be incorporated into a dry fertilizer for application using the fertilizer itself or a component of the fertilizer such as one or more of the fillers commonly used in fertilizers.

Abstract: Disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 40% to about 95% water; wherein the pH of the composition is greater than about 7. Further disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 0.1% to about 5% of a zinc ionophoric material; from about 40% to about 95% water; and wherein the pH of the composition is greater than about 7.

Abstract: A method of making a composition having the property of being able to store chlorine dioxide includes mixing an aqueous chlorine dioxide solution with a superabsorbent, water-soluble polymer that is substantially unreactive with chlorine dioxide and permitting a mixture formed thereby to form one of a gel and a solid composition. A method of delivering chlorine dioxide includes providing a gel or solid composition as described and degelling the gel or dissolving the solid composition to dispense the chlorine dioxide therefrom. A method of disinfecting a target such as water, wastewater, or a surface comprises delivering chlorine dioxide as above and permitting the polymer to precipitate out of the mixture. Aqueous chlorine dioxide is then recovered and applied to the target.

Abstract: The invention relates to a novel injectable liquid formulation of paracetamol, comprising an aqueous solvent, a buffer agent with a pKa between 4.5 and 6.5, an isotonic agent and the dimer of paracetamol of formula (I), a method for preparation of said formulation and the use of said dimer for the stabilisation of a liquid paracetamol pharmaceutical formulation.

Abstract: Parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl) -2-methylpropionic acid (CCI-779) are provided. One parenteral formulation contains CCI-779, an alcoholic co-solvent, and an antioxidant. Another parenteral formulation contains CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant. Processes for preparing parenteral CCI-779 formulations using a co-solvent concentrate are also provided.

Abstract: Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized pharmaceutical formulation is instilled in the bladder for a time sufficient to treat the cancer.

Abstract: The present invention provides a base composition that allows for the formulation of non-irritating cosmetic and/or dermatological compositions. The base composition includes one or more of electrolyte, buffer, mild preservative, lubricant, or any combinations thereof. It is preferred that one or more of the above components are eye-safe and/or eye-compatible. The present invention also provides photoprotective cosmetic and/or dermatological compositions that include the base composition and one or more sunscreen active components and are non-irritating to mammalian eyes.

Abstract: A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth regulator (IGR). The topical insecticide preparation can be packaged together or packaged so that the first and second pyrethroid insecticides are stored separately prior to administration of the insecticide preparation to the animal. The combination of the first and second pyrethroid insecticides with an insect growth regulator results in an insecticide preparation formulated to have enhanced insecticidal activity against fleas and ticks compared to the effectiveness of the first and second insecticides used alone.

Abstract: Novel pharmaceutical gallium compositions, including gallium complexes having increased oral bioavailability relative to uncomplexed gallium salts are disclosed. Such compositions are useful in the treatment of conditions and diseases in which inhibition of abnormally increased calcium resorption is desired, including cancer, hypercalcemia, osteoporosis, osteopenia and Paget's disease. Methods for preparation and treatment are also provided.

Abstract: The present invention provides an aqueous composition comprising—water; —a water miscible solvent; —and a polyene fungicide which is dissolved in the water and water miscible solvent. The present invention further provides a method for the production of the composition of the invention. The composition of the invention may be used as an antifungal treatment for a variety of products including food, feed, agricultural products, growth substrates and in- or outsides of buildings.

Abstract: The present invention relates to oral pharmaceutical preparations in the form of pellets in which a benzimidazole compound is stabilized by combining it with microcrystalline cellulose.

Abstract: Compositions for topical application for treating a skin disorder (e.g., acne) include a retinoid, which is solubilized completely in alcohol only with the aid of cosolvents such as esters (e.g., alkyl benzoate, isopropyl palmitate, isopropyl myristate, diisopropyl adipate and their derivatives). This completely solubilized retinoid can be used to formulate an emulsion system or liquid to powder suspension containing a second active, such as an antibiotic (e.g., clindamycin).

Abstract: An enhanced activity aqueous disinfecting solution having a pH of from about 0.5 to about 6 and consisting essentially of (i) hydrogen peroxide in a concentration of from about 0.

Abstract: The invention relates to a method for inhibiting the biological acidification of water which is in contact with materials containing sulfur in reduced form or with elemental sulfur, susceptible to oxidation on the part of Thiobacilli, comprising putting said materials in contact with soluble inorganic salts at concentrations ranging from 0.4 normal to saturation.

Abstract: A method for producing a suspension, emulsion or dispersion of de-agglomerated particles (advantageously submicron-sized particles) of pyrithione salts comprising contacting agglomerated pyrithione salt particles with a de-agglomerating agent to produce the desired de-agglomerated pyrithione salt particles. Also disclosed is a method for making de-agglomerated submicron-sized particles of pyrithione salts comprision a heating step. Also disclosed are the particles made by the above methods and compositions comprising the particles and a base medium.

Abstract: A nanocolloidal platinum dispersion comprising nanocolloidal platinum and a polyacrylic acid salt, the nanocolloidal platinum having an average particle size of 1-5 nm, 90% or more of the nanocolloidal platinum having a particle size in a range of 0.1-10 nm, its production method, and a drink containing such a nanocolloidal platinum dispersion.

Abstract: A pseudo-plastic or thixotropic carrier having anti-malodorous components dissolved or suspended therein is sprayed on the internal surfaces of an ostomy bag or pouch. The viscoelastic properties of the carrier allow the composition to be conveniently dispensed from a spray bottle into the ostomy bag and retained on the inner walls thereof without being displaced therefrom by incoming waste during use of the ostomy bag. This allows the composition to continue to deodorize the ostomy bag headspace even after waste material begins to fill the bag.

Abstract: Formulations containing an antibacterial alkali metal salt of a cephalosporin compound and methods of treating bacterial infections in dogs and cats.

Abstract: A liquid, cold-temperature-stabilized preservative is based on carbendazim or a salt thereof, which includes, as low-temperature stabilizer, at least one aromatic alcohol and/or at least one aromatic glycol ether and/or a pyrrolidone.

Abstract: A topical formulation having significant parasiticidal activity effective against endoparasites and/or ectoparasites such as heartworms, mites, fleas, ticks, flies is provided, which can be safe to use and avoids the many common deleterious side effects of conventional topical formulations. The topical formulations comprise a combination of a macrocyclic lactone, a neo-nicotinoid and optionally, an insect growth regulator. The topical formulation can be packaged together or packaged so that the macrocyclic lactone and the neo-nicotinoid are stored separately prior to administering the topical insecticide formulation to the animal.

Abstract: A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth regulator (IGR). The topical insecticide preparation can be packaged together or packaged so that the first and second pyrethroid insecticides are stored separately prior to administration of the insecticide preparation to the animal. The combination of the first and second pyrethroid insecticides with an insect growth regulator results in an insecticide preparation formulated to have enhanced insecticidal activity against fleas and ticks compared to the effectiveness of the first and second insecticides used alone.

Abstract: The present invention provides methods of preventing and/or treating multiple organ failure comprising the step of administering a therapeutically effective amount of agent comprising tumor cytotoxic factor-II (TCF-II) or hepatocyte growth factor (HGF). Methods of the present invention will be useful for preventing and/or treating the development of multiple organ failure resulting from burn, disseminated intravascular coagulation (DIC), circulatory failure, hemorrhagic shock, infectious disease, acute pancreatitis, ischemic disorder, hepatorenal syndrome, gastrointestinal hemorrhage, nutritional metabolic failure, terminal cancer, acquired immunodeficiency syndrome (AIDS), deterioration of systemic conditions due to radiation affection, and cachexia.

Abstract: A non-toxic environmentally friendly aqueous disinfectant is disclosed for specific use as prevention against contamination by potentially pathogenic bacteria and virus. The aqueous disinfectant is formulated by electrolytically generating silver ions in water in combination with a citric acid. The aqueous disinfectant may include a suitable alcohol and/or a detergent. The aqueous disinfectant has been shown to be very effective at eliminating standard indicator organisms such as staphylococcus aureus, salmonella cholerasuis and pseudomonas aeruginosa.

Abstract: A non-stoichiometric clathrate of lipid and sulfur has been shown to effectively stabilize nerve cell membranes. As such, said compound has proven useful in a variety of neuropsychiatric disorders such as, addiction, depression, autism, Tourette's syndrome, and the like.

Abstract: Processes for preparing products comprising an oxygen-generating additive for reducing the amount of skin irritation and inflamation and odor are disclosed. Specifically, products such as training pants and diapers are disclosed which contain a carbohydrate-hydrogen peroxide crystalline powder which, when wetted, produces a stream of oxygen which can be used by various bacteria on and near the wearer's skin during metabolism resulting in a significant decrease in the amount of volatile organic compounds produced by the bacteria during metabolism.

Abstract: A method of making a composition having the property of being able to store chlorine dioxide includes mixing an aqueous chlorine dioxide solution with a superabsorbent, water-soluble polymer that is substantially unreactive with chlorine dioxide and permitting a mixture formed thereby to form one of a gel and a solid composition. A method of delivering chlorine dioxide includes providing a gel or solid composition as described and degelling the gel or dissolving the solid composition to dispense the chlorine dioxide therefrom. A method of disinfecting a target such as water, wastewater, or a surface comprises delivering chlorine dioxide as above and permitting the polymer to precipitate out of the mixture. Aqueous chlorine dioxide is then recovered and applied to the target.

Abstract: An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.

Abstract: This invention provides a microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant. The active agent may be a cyclosporin or a macrolide. In another aspect, this invention provides a pharmaceutical composition for enteral or parenteral administration comprising a macrolide and an acid.

Abstract: The present invention relates to a liquid pharmaceutical composition consisting essentially of an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0, and optionally one or more pharmaceutically acceptable excipients. This composition is especially useful for the prophylaxis and treatment of diseases related to erythropoiesis.

Abstract: A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.

Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.

Abstract: A composition including 2-hexyl cyanoacrylate and gold is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.